c-erbB-2 protein level in tissue and sera of breast cancer patients: A possibly useful clinical correlation

Tumori

Volumn 92, Issue 4, 2006, Pages 311-317

  Quaranta, Michele ^a   Daniele, Antonella ^a   Coviello, Maria ^a   Savonarola, Annalisa ^a   Abbate, Ines ^a   Venneri, Maria Teresa ^a   Paradiso, Angelo ^a   Stea, Baldassarre ^a   Zito, Alfredo ^a   Labriola, Angela ^a   Schittulli, Francesco ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Breast cancer; c erbB 2; p105

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; PROTEIN P105; THYROID HORMONE RECEPTOR BETA;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE INTERVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE; MAJOR CLINICAL STUDY; PREOPERATIVE PERIOD; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TISSUE CULTURE; TUMOR VOLUME;

EID: 33749534006     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160609200409     Document Type: Article

References (35)

1. Hynes NE, Stern DF: The biology of erbB-2/neu and its role in cancer. Biochim Biophys Acta, 1198: 165-184, 1994.
2. Maguire HC, Greene MI: The neu (c-erbB-2) oncogene. Semin Oncol, 16: 148-155, 1989.
3. Hung MC, Lau YK: Basic science of HER-2/neu: A review. Semin Oncol, 26 (Suppl 12): 51-59, 1999.
4. Hanna W, Kahn HJ, Trudeau M: Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside. Mod Pathol, 12: 827-834, 1999.
5. Yu D, Wang S-S, Dulski KM, Tsai CM, Nicolson GL, Hung MC: C-erbB-2 /neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res, 54: 3260-3266, 1994.
6. erbB2. Science, 249: 1552-1555, 1990.
7. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene. Science, 235: 177-182, 1987.
8. Singleton TP, Strickler JG: Clinical and pathological significance of the c-erbB-2 (HER-2/neu) oncogene. Pathol Annu, 27: 165-190, 1992.
9. Lovekin C, Ellis IO, Locker A, Robertson JFR, Bell J, Nicholson RI, Gullick WJ, Elston CW, Blamey RW: c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer, 63: 439-443, 1991.
10. Molina MA, Codony-Servant J, Albanell J, Rojo F, Arribas J, Baselga J: Trastuzumab (Herceptin), a humanized anti HER2 receptor monoclonal antibody, inhibits basal and actived HER2 ectodomain cleavage in breast cancer cells. Cancer Res, 61: 4744-4749, 2001.
11. Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP: Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem, 49: 579-598, 2003.
12. Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, Massutì B, Cortés-Funes H, Lloveras B: Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res, 6: 2356-2362, 2000.
13. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco AR, De Placido S: c-erbB-2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol, 14: 2702-2708, 1996.
14. Newby JC, Johnston SRD, Smith IE, Dowsett M: Expression of epidermal growth factor receptor and c-erbB-2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res, 3: 1643-1651, 1997.
15. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchlist KW, Monsour EG, Abeloff M, Eudey L: Her-2/neu in node negative breast cancer: Prognostic significance of overexpression influenced by presence of in situ carcinoma. J Clin Oncol, 10: 599-605, 1992.
16. Zabrecky JR, Lam T, McKenzie SJ, Carney W: The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem, 266: 1716-1720, 1991.
17. Pupa SM, Menard S, Morelli D, Pozzi B, De Palo G, Colnaghi MI: The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene, 8: 2917-2923, 1993.
18. Kraus MH, Popescu NC, Amsbaugh SC, King CR: Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J, 6: 605-610, 1987.
19. Mansour EG, Ravdin PM, Dressler L: Prognostic factors in early breast carcinoma. Cancer, 74: 381-400, 1994.
20. Schmitt FC, Figueireido P, Lacerda M: Expression of c-erbB2 protein and DNA ploidy in breast carcinogenesis. Arch Pathol Lab Med, 119: 815-820, 1995.
21. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Frequa SA, Killander D, McGuire WL: HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res, 50: 4332-4337, 1990.
22. Tetu B, Brisson J: Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer, 14: 2702-2708, 1994.
23. +) breast cancer patients with poor prognosis. Ann Oncol, 12: 525-533, 2001.
24. Hermanek P, Sobin LH (Eds), International Union Against Cancer (UICC): TNM classification of malignant tumors, 4th Ed, Springer Verlag, Berlin, 1987.
25. McKenzie SJ, Marks PJ, Lam T, Morgan J, Panicali DL, Trimpe KL, Carney WP: Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene, 4: 543-548, 1989.
26. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53: 457-481, 1958.
27. Cox DR: Statistical significance tests. Br J Clin Pharm, 14: 325-331, 1982.
28. Kandl H, Seymour L, Bezwoda WR: Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. Br J Cancer, 70: 739-742, 1994.
29. Codony-Servant J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J: Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res, 59: 1196-1201, 1999.
30. Kokichi S, Mineko U, Takashi F, Hitoshi T, Takashi K, Hisanao O: Combined measurement of the c-erbB-2 protein in breast carcinoma tissue and sera is useful as a sensitive tumor marker for monitoring tumor relapse. Int J Cancer, 89: 329-336, 2000.
31. Dowsett M, Cooke T, Ellis I, Gullick WJ, Gusterson B, Mallon E, Walker R: Assessment of HER status in breast cancer: why, when and how? Eur J Cancer, 36: 170-176, 2000.
32. Yamauchi H, Steams V, Hayes DF: When is a tumor marker ready for prime time? A case study of C-erbB-2 as a predictive factor in breast cancer. J Clin Oncol, 19: 2334-2356, 2001.
33. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet, 2: 171-175, 1987.
34. Fisher ER, Sass R, Fisher B, Gregorio R, Brown R, Wickerham L: Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6): II. Relation of local breast recurrence to multicentricity. Cancer, 57: 1717-1724, 1986.
35. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer. An overview of the randomised trials. Lancet, 351: 1451-1467, 1998.